The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case–control study by Dixon, W G et al.
Extended report
Ann Rheum Dis 2011;70:956–960. doi:10.1136/ard.2010.144741 956
  
Accepted 2 January 2011
Published Online First 
1 February 2011
  ABSTRACT 
  Background      Glucocorticoid therapy is strongly 
associated with an elevated risk of serious infections in 
patients with rheumatoid arthritis (RA). The association 
between glucocorticoids and common non-serious 
infections (NSI) is not well studied.   
  Methods      A cohort of 16 207 patients with RA aged 
over 65 years was assembled using administrative data 
from Quebec. Glucocorticoid and disease-modifying 
antirheumatic drug (DMARD) therapy were identiﬁ  ed 
from drug dispensing records. NSI cases were deﬁ  ned 
as ﬁ  rst occurrence of a community physician billing code 
for infection or community-dispensed anti-infectives. A 
nested case–control analysis was performed considering 
drugs dispensed within 45 days of the index date, 
adjusting for age, sex, markers of disease severity, 
DMARD and comorbidity.   
  Results      For 13 634 subjects, a NSI occurred during 
28 695 person-years of follow-up, generating an 
incidence rate of 47.5/100 person-years. The crude rate 
of NSI in glucocorticoid-exposed and unexposed person 
time was 52.4 and 38.8/100 person-years, respectively. 
Glucocorticoid therapy was associated with an adjusted 
RR of 1.20 (95% CI 1.15 to 1.25). A dose response was 
seen, the adjusted RR increasing from 1.10 (<5 mg 
prednisolone/day) to 1.85 for doses greater than 20 
mg/day. All glucocorticoid risk estimates (including <5 
mg/day) were higher than that seen for methotrexate 
(adjusted RR 1.00; 0.95 to 1.04).   
  Conclusion      Glucocorticoid therapy is associated 
with an increased risk of NSI. The magnitude of risk 
increases with dose, and is higher than that seen with 
methotrexate, although residual confounding may exist. 
While the RR is low at 1.20, the absolute risk is high with 
one additional infection seen for every 13 patients treated 
with  glucocorticoids  for  1  year.      
  Glucocorticoid therapy was introduced as a treat-
ment for patients with rheumatoid arthritis (RA) 
nearly 60 years ago.    1    Approximately one third of 
patients with RA are current users, and two thirds 
of patients have ever used steroids.    2    Although glu-
cocorticoid therapy improves the symptoms of 
active RA    3    and modiﬁ  es disease progression,    4    there 
have long been concerns about safety. One of the 
major risks associated with glucocorticoid therapy 
is infection, along with others including cardiovas-
cular disease, diabetes and osteoporosis.    5    
  The association between glucocorticoid therapy 
and serious infection (generally deﬁ  ned as infection 
leading to hospitalisation, intravenous antibiotics, 
signiﬁ  cant loss of function or disability or death) is 
now well established in observational studies.    6–15    
Randomised clinical trials are often too small and 
thus underpowered to detect risks of serious infec-
tions. The risk of infection is dose-dependent,    10        11        13    
although it is not clear if there is a threshold below 
which glucocorticoid therapy is safe. Comparisons 
with the risk associated with other traditional 
disease-modifying antirheumatic drugs (DMARD) 
suggest glucocorticoid therapy has a higher RR.    6–12    
  To date, little research has explored the associa-
tion between glucocorticoid therapy and non-seri-
ous infection (NSI) in patients with RA. Although 
these events are not life-threatening, the burden 
of NSI is high. Non-serious respiratory infections 
account for 300–400 general practice consultations 
annually per 1000 registered patients in the UK.    16    
Even a modest increase in the RR of NSI with glu-
cocorticoid therapy could therefore represent a 
large increase in the absolute or attributable risk 
and a signiﬁ  cant health burden. 
  Our primary aim was to test the hypothesis that 
systemic glucocorticoid therapy is associated with 
an increased risk of NSI in patients with RA com-
pared with patients with RA not treated with glu-
cocorticoids using a nested case–control analysis. 
Secondary aims were to estimate the attributable 
risk associated with glucocorticoids, explore any 
dose-dependent risk and to compare the glucocor-
ticoid-associated risk with the risk associated with 
other DMARD treatments. 
  METHODS 
  A cohort study and nested case–control analysis 
was conducted to examine the inﬂ  uence of sys-
temic glucocorticoid therapy upon the risk of NSI 
in patients with RA. Ethical approval was obtained 
from the McGill University Institutional Review 
Board. 
  Study  base 
  Patients with RA were assembled from the admin-
istrative databases of the Régie de l’assurance mala-
die du Québec (RAMQ) and the Ministry of Health’s 
Maintenance et Exploitation des Données pour 
l’Étude de la Clientèle Hospitalière (MEDECHO). 
The RAMQ is responsible for administering uni-
versal healthcare services for the province of 
Québec, Canada. It contains three databases linked 
by an individual’s unique health insurance number: 
a demographic database, a medical services data-
base and a prescription database. The demographic 
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  Exposure 
  All drugs dispensed in the 45 days before the index date were 
identiﬁ  ed from the prescription database. Systemic glucocorti-
coid therapy (oral, intravenous or intramuscular injection) was 
identiﬁ  ed using unique drug identiﬁ  cation numbers obtained 
from the Drug Product Database of Health Canada.    17    Current 
glucocorticoid exposure was categorised as yes/no, current expo-
sure deﬁ  ned as any prescription dispensed within the 45-day 
period before the index date. Four sensitivity analyses were con-
ducted by varying the time window for any prescription to 15, 
30, 90 and 180 days before the index date. The glucocorticoid 
dosage was converted to daily prednisolone equivalent dosage 
(PEQ), and categorised as 0, 0.1–4.9, 5–9.9, 10–14.9, 15–19.9 and 
20 mg PEQ and above. A dose of glucocorticoid therapy was 
considered for oral therapy only.   
  Statistical  analysis 
  Person-years of follow-up within the whole cohort were 
totalled to estimate the incidence rates of a ﬁ  rst NSI. Incidence 
rates were also separately calculated for person time exposed 
or not exposed to glucocorticoid therapy. In this cohort anal-
ysis, exposed time began on the day of glucocorticoid dis-
pensing and continued for the duration of the glucocorticoid 
prescription. 
  Within the nested case–control analysis, conditional logistic 
regression was used to calculate the OR and 95% CI for infec-
tion for systemic glucocorticoid therapy, as well as DMARD. 
Using risk-set sampling, the estimated OR can be interpreted as 
a rate ratio or RR.    18    Results are presented as RR with 95% CI. 
Sequential analyses exploring the RR conferred by glucocorti-
coid therapy (oral, injectable or either) were undertaken, ﬁ  rst 
adjusting for age and sex, then concurrent DMARD therapy, 
then all a priori confounders. The association of DMARD use 
and NSI was also reported, adjusted for all other drugs to pro-
vide estimates of the independent effects of each drug, then 
further adjusted for the a priori confounders. All analyses were 
performed using SAS (version 9.2).   
  Potential  confounders 
  Disease severity and comorbidity were both potential con-
founders. No direct measures of disease severity exist within 
RAMQ, and therefore several surrogate markers were included 
in the analysis (number of rheumatologist visits in the pre-
ceding 6 months, current non-steroidal anti-inﬂ  ammatory 
drug (NSAID) use, previous code for extra-articular RA). 
Comorbidity was identiﬁ  ed from diagnoses made before the 
index date, using ICD-9 codes for physician encounters (inpa-
tient or outpatient) of diabetes mellitus, chronic respiratory 
conditions (chronic obstructive pulmonary disease, asthma 
or interstitial lung disease), cancer, chronic renal disease and 
osteoporosis. These comorbidities were also identiﬁ  ed from 
medication typically associated with its treatment (eg, insulin 
for diabetes). The comorbidity items were chosen because of 
their potential association with both glucocorticoid exposure 
and with the risk of infection. Other covariates included in the 
model were age, sex and gastric acid-suppressive drugs, given 
their possible association with both glucocorticoid use and 
infection risk.    19        
  RESULTS 
  Overall, 16 207 patients with RA aged >65 were identiﬁ  ed. Two-
thirds of the cohort were women, and the mean age was 71 
years (  table 1  ). The most commonly prescribed DMARD were 
database contains information on age and sex for all registered 
eligible healthcare beneﬁ   ciaries in Québec. The medical ser-
vices database contains the date and location of appointments, 
specialty of the treating and referring physician and the diag-
nostic code of the billed service (International Classiﬁ  cation 
of Diseases (ICD-9) code). The prescription database contains 
information on dispensed outpatient prescription medications 
including drug name, dosage and amount dispensed, date dis-
pensed and prescribed number of days of treatment. The pre-
scription programme is restricted to individuals 65 years of 
age and older, welfare recipients and individuals without pri-
vate drug insurance through their employer. The MEDECHO 
database records data on acute care hospital admissions for all 
residents of Québec. Data exist on the primary and up to 15 
secondary discharge diagnoses, date of admission, duration of 
hospital stay and treatments received while in hospital.   
  Study  population 
  The study population from which the cohort was formed con-
sisted of all patients with RA aged over 65 years who, between 
1 January 1985 and 31 December 2003, were dispensed at least 
one traditional or biological DMARD in the RAMQ prescrip-
tion programme. RA was identiﬁ  ed from the physician billing 
code (ICD-9 code 714). Eligible DMARD included methotrex-
ate, sulfasalazine, leﬂ   unomide, hydroxychloroquine, chloro-
quine, azathioprine, cyclophosphamide, cyclosporine, gold 
compounds, mycophenolate mofetil, d-penicillamine and the 
anti-tumour necrosis factor (TNF) agents inﬂ  iximab, etanercept 
and adalimumab. Cohort entry was deﬁ  ned as the date of ﬁ  rst 
DMARD prescription following an RA diagnosis, or 1 January 
1985  , whichever came later. The age restriction of over 65 years 
was to ensure complete prescription records from RAMQ for the 
whole population. Subjects were all followed from the cohort 
entry date to the earliest outcome of interest, death or the end 
of study period (31 December 2003). Subjects were required to 
have more than 3 months of eligibility in the health insurance 
plan before cohort entry.   
  Deﬁ  nition of cases and controls 
  NSI cases were deﬁ  ned as the ﬁ  rst occurrence of either a phy-
sician billing code for infection or community-dispensed anti-
infectives, taking the ﬁ  rst occurrence of either as the index case. 
A sensitivity analysis was performed requiring cases to have 
both a billing code and an anti-infective, when the billing code 
preceded the anti-infective prescription by 1 week or less. This 
deﬁ  nition would include a higher proportion of deﬁ  nite infec-
tions but would miss a large number of genuine infections in 
which either the single billing code did not capture the infection 
or anti-infectives were appropriately not prescribed. The codes 
for infection are listed in supplementary appendix A, available 
online only in supplementary ﬁ  le 1. Cases were therefore sub-
jects with a ﬁ  rst NSI (with its index date), occurring between 
cohort entry and 31 December 2003. 
  For each NSI that occurred in the cohort, we identiﬁ  ed a ‘risk 
set’ of patients who had not yet developed a NSI by that index 
date, but who remained at risk. For each case, we randomly 
selected ﬁ  ve controls from the risk set, matched on entry date 
and time in cohort. The date of NSI was designated as the index 
date for each case–control set. Controls could later be included 
as cases, and a patient acting as a control for one case could 
be selected again as a control for future cases during the study 
period. One patient could therefore act many times as a control 
during their follow-up, albeit at different times.   
13_annrheumdis144741.indd   957 13_annrheumdis144741.indd   957 4/23/2011   11:42:13 AM 4/23/2011   11:42:13 AMExtended report
Ann Rheum Dis 2011;70:956–960. doi:10.1136/ard.2010.144741 958
patients had had a systemic glucocorticoid injection in the 45 
days before the index date. The association between injectable 
glucocorticoid therapy and infection was inconclusive, with 
possible effect sizes ranging from a slight protective effect to 
a 22% increased risk. Too few patients (<1%) were dispensed 
both oral and injectable glucocorticoid therapy to enable robust 
effect estimates. 
  Current exposure to methotrexate was associated with no 
increased risk of infection compared with no methotrexate (aRR 
1.00, 0.95 to 1.04;  table 4 ). Patients currently prescribed sulfasala-
zine or antimalarials had a lower rate of infection than those not 
prescribed those drugs. Cyclophosphamide was associated with 
a higher risk of infection (aRR 2.14, 1.51 to 3.03). The results 
for anti-TNF therapy were inconclusive given the small number 
of patients exposed to them. Gastric acid-suppressive drug pre-
scription (proton pump inhibitors or H2 blockers) in the 45 days 
before the index date was associated with an increased risk of 
NSI (aRR 1.36, 1.30 to 1.43). 
  In order to explore the validity of the event deﬁ  nition, we per-
formed a sensitivity analysis by requiring any NSI to have both 
a billing code and an anti-infective prescription within a week of 
each other. The aRR of NSI for oral glucocorticoid exposure in 
the preceding 45 days using the stricter outcome deﬁ  nition was 
1.09 (0.98 to 1.22).   
the antimalarials chloroquine and hydroxychloroquine (43%) 
followed by methotrexate (38%). Less than 1% of patients 
were treated with anti-TNF drugs, reﬂ  ecting the introduction 
of biological therapy late in the calendar period of the study. 
During the study period, there were 13 634 ﬁ  rst-episode NSI 
during 28 695 person-years of follow-up, generating an overall 
incidence rate of 47.5/100 person-years. The commonest site of 
infection was the respiratory tract. The crude rate of NSI in glu-
cocorticoid-exposed and unexposed person time was 52.4 and 
38.8/100 person-years, respectively. The 13 634 patients with 
ﬁ  rst episodes of NSI comprised the cases for the nested case–
control analysis. 
  Cases and controls had similar age and sex proﬁ  les, despite 
being matched only on entry date and time in cohort (  table 2  ). 
The mean age was slightly higher in the cases and controls than 
it was for the whole cohort. The cases had more extra-articular 
RA and more general practitioner and hospital specialist visits 
in the year before the index date. They also had a higher preva-
lence of all comorbidities (diabetes, chronic respiratory disease, 
osteoporosis, chronic renal disease and cancer), and more com-
monly used gastric acid suppressants. 
  Approximately 35% of patients had current exposure to glu-
cocorticoid therapy. Exposure to current glucocorticoid therapy 
was associated with an increased risk of NSI (age and sex-
adjusted RR (aRR) 1.28, 95% CI 1.23 to 1.33;   table 3  ). Further 
adjustment for concurrent DMARD therapy made little differ-
ence to the estimate, although additional adjustment for the a 
priori confounders reduced the estimate to 1.20 (1.15 to 1.25). 
Adjusting the deﬁ  nition of current glucocorticoid exposure to 
prescriptions dispensed within 15, 30, 90 or 180 days before 
the index date resulted in aRR estimates of 1.22 (1.16 to 1.28), 
1.21 (1.16 to 1.26), 1.18 (1.13 to 1.23) and 1.16 (1.11 to 1.20), 
respectively. 
  Using the unexposed cohort event rate of 38.8/100 person-
years and the aRR of 1.20, the attributable risk from gluco-
corticoid therapy was 7.8/100 person-years. In other words, 
for every 13 patients treated with glucocorticoid therapy over 
a 1-year period, there would be one additional NSI compared 
with patients not treated with glucocorticoids. 
  The most commonly dispensed dose of oral glucocorticoid 
therapy was between 5 and 9.9 mg PEQ per day. All dose 
categories of oral glucocorticoid therapy appeared to have an 
increased RR of infection, with a noticeably higher risk at doses 
greater than 20 mg PEQ per day. There appeared to be a step-
wise increased risk associated with increasing dose through 
the dose categories, notably at 10 and 20 mg PEQ. Only 2% of 
  Table  2          Baseline characteristics of cases and matched controls from a 
base population of 16 207 RA patients, 1985–2003   
   Cases   Controls* 
Number 13 634 68 170
Age (years, mean (SD)) 71.9 (6.0) 71.8 (5.9)
Sex (% women) 68.9 68.9
Follow-up (years, mean (SD)) 1.2 (1.5) 1.2 (1.5)
Number of rheumatologist visits in 6 months 
before index date (mean (SD))
1.5 (2.7) 1.4 (2.5)
NSAID prescription within last 45 days 55.2 55.7
Extra-articular RA 0.2 0.1
DMARD prescription within past 45 days†
 Methotrexate 33.3 33.0
 Sulfasalazine 2.4 3.0
 Leﬂ   unomide 0.3 0.3
 Chloroquine/hydroxychloroquine 29.4 30.7
 Azathioprine 1.9 1.5
 Cyclophosphamide 1.7 0.7
 Anti-TNF  therapy 0.1 0.1
 Gold 7.1 6.5
  Others (ciclosporin, mycophenolate mofetil, 
d-penicillamine)
1.8 1.7
No of hospital admissions in year preceding index 
date (mean (SD))
0.5 (1.0) 0.4 (0.8)
No of GP visits in year preceding index date (mean 
(SD))
7.8 (9.0) 6.1 (7.7)
No of hospital specialist visits (excluding 
rheumatologist) in year preceding index date 
(mean (SD))
9.9 (13.1) 7.6 (10.8)
Comorbidity (from ICD-9 or drug codes)
 Diabetes 9.3 7.8
  Chronic respiratory disease (COPD/asthma/ILD) 20.3 12.1
 Osteoporosis 17.9 15.6
  Chronic renal disease 20.3 12.1
 Cancer 4.3 2.7
PPI/H2 blocker prescription within last 45 days 27.9 20.0
      Numbers are percentages unless otherwise stated. 
  *Each patient within the cohort could contribute more than once to the controls. 
  †Patients could receive combination disease-modifying antirheumatic drug (DMARD) 
therapy and contribute to more than one drug category. 
  COPD, chronic obstructive pulmonary disease; GP, general practitioner; ICD, International 
Classiﬁ  cation of Diseases; ILD, interstitial lung disease; NSAID, non-steroidal anti-
inﬂ  ammatory drug; PPI, proton pump inhibitor; RA, rheumatoid arthritis.     
  Table  1          Baseline characteristics of RA subjects at cohort entry 
(n=16 207)   
Age (years, mean (SD)) 70.9 (5.9)
Female (number (%)) 68.3
DMARD use at cohort entry*
 Methotrexate 37.9
 Sulfasalazine 3.3




 Anti-TNF  therapy 0.01
 Gold 10.6
  Others (ciclosporin, mycophenolate mofetil, d-penicillamine) 2.8
      *Patients could receive combination disease-modifying antirheumatic drug (DMARD) 
therapy and contribute to more than one drug category, allowing total to exceed 100%. 
  RA, rheumatoid arthritis; TNF, tumour necrosis factor.     
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  The strengths of this study include its size. We were able 
to identify over 13 000 patients with an infection in a patient 
population of over 16 000 patients. Although this meant that 
individual subjects were selected more than once as controls, 
this is necessary within nested case–control analyses to avoid 
the introduction of bias.    21    The administrative setting meant 
that there was no selection bias, as we were able to study the 
whole population over 65 years. Indeed, this older population is 
at higher background risk of infection and is of particular clinical 
interest. 
  Limitations do exist in this administrative database study. 
Patients with RA were identiﬁ   ed using billing codes, intro-
ducing the possible misclassiﬁ   cation of patients with other 
musculoskeletal diseases. The additional requirement for a 
DMARD prescription should, however, minimise this problem. 
Glucocorticoid exposure was ascertained from dispensary data. 
Once dispensed, it is possible that patients were non-adherent. 
This could include patients not taking medication that was dis-
pensed, or alternatively taking cached medication. Such patient 
decisions may be inﬂ  uenced by disease activity. Any resultant 
misclassiﬁ  cation of the exposure could be differential in either 
direction and could bias the result either towards or away from 
the null. We have considered the inﬂ  uence of only current glu-
cocorticoid exposure upon the risk of NSI. Although more com-
plex methods exist to model the relationship ﬂ  exibly between 
time-varying dose and outcome, our analysis methodology 
matches that of previous studies, thereby making the results 
more comparable. Furthermore, it makes biological sense that 
  DISCUSSION 
  Exposure to current oral glucocorticoid therapy was associated 
with a 20% increased risk of infection. The magnitude of this 
increased risk was slightly higher than that seen with metho-
trexate. This risk can be expressed as a number needed to harm, 
in which for every 13 patients treated with glucocorticoid ther-
apy over a 1-year period (assuming a constant hazard), there 
was one additional NSI. Whereas the risk appeared greater with 
any current oral glucocorticoid therapy compared with none, 
there was a dose–response relationship, and the risk was clearly 
greater at daily doses above 20 mg PEQ per day (aRR 1.85, 1.68 
to 2.05). 
  These results replicate the ﬁ   ndings of another Canadian 
administrative database study, which found an aRR of 1.15 
(1.11 to 1.19) for mild (ie, non-serious) infections comparing 
oral glucocorticoid therapy with no glucocorticoid or DMARD 
therapy.    7    Allowing for some differences between the studies, 
this near-identical result adds weight to the observed associa-
tion, although similar biases in the two studies cannot be ruled 
out. Many studies of serious infection exist, with RR estimates 
for all-site serious infection ranging from 1.5 to 2.5.    6–10    Similar 
estimates exist for site-speciﬁ  c    11        12    and organism-speciﬁ  c    13        14        20    
serious infection. Although the magnitude of RR is not as high 
with non-serious compared with serious infections, the baseline 
rate of NSI is much greater. This means that, despite the lower 
RR for NSI, the actual number of additional cases attributed to 
glucocorticoid therapy is greater for non-serious compared with 
serious infection. 
  Table  3          Effect of current glucocorticoid therapy upon non-serious infection (billing code or anti-infective prescription), stratiﬁ  ed by mode of 






 Crude  RR 
(95% CI) 
  RR, adjusted for age 
and sex only (95% CI) 
  RR, adjusted for age and 
sex and DMARD (95% CI)    Adjusted RR* (95% CI) 
Oral glucocorticoid exposure 
within past 45 days
37.9 32.5 1.28 (1.23 to 1.33) 1.28 (1.23 to 1.33) 1.28 (1.23 to 1.34) 1.20 (1.15 to 1.25)
Average daily dose of glucocorticoid therapy
  <5 mg PEQ 3.2 3.1 1.13 (1.01 to 1.25) 1.13 (1.01 to 1.25) 1.13 (1.02 to 1.26) 1.10 (0.99 to 1.22)
  5–9.9 mg 17.8 17.1 1.15 (1.09 to 1.20) 1.15 (1.09 to 1.20) 1.15 (1.10 to 1.21) 1.10 (1.04 to 1.16)
  10–14.9 mg 9.5 7.9 1.33 (1.25 to 1.42) 1.33 (1.25 to 1.42) 1.34 (1.26 to 1.44) 1.25 (1.17 to 1.34)
  15–19.9 mg 2.7 2.1 1.41 (1.25 to 1.58) 1.41 (1.25 to 1.58) 1.40 (1.25 to 1.58) 1.26 (1.12 to 1.42)
  ≥20 mg 4.7 2.3 2.33 (2.11 to 2.56) 2.33 (2.11 to 2.56) 2.27 (2.06 to 2.50) 1.85 (1.68 to 2.05)
Systemic glucocorticoid 
injection within past 45 days
2.2 1.8 1.18 (1.04 to 1.34) 1.18 (1.04 to 1.34) 1.18 (1.04 to 1.34) 1.07 (0.94 to 1.22)
Any glucocorticoid: oral or injection39.2 33.7 1.28 (1.23 to 1.33) 1.28 (1.23 to 1.33) 1.29 (1.24 to 1.34) 1.19 (1.14 to 1.24)
Numbers are percentages unless otherwise stated.
      *Adjusted for all a priori confounders listed in   table 2  . 
  DMARD, disease-modifying antirheumatic drug; PEQ, prednisolone equivalent dose.     





(n=68 170)    aRR, model 1 (95% CI)    aRR, model 2 (95% CI) 
Current DMARD use
  Methotrexate 33.3 33.0 0.98 (0.94 to 1.03) 1.00 (0.95 to 1.04)
  Sulfasalazine 2.4 3.0 0.81 (0.72 to 0.91) 0.79 (0.70 to 0.89)
  Leﬂ  unomide 0.3 0.3 1.07 (0.76 to 1.49) 1.00 (0.71 to 1.39)
  CQ/HCQ 29.4 30.7 0.91 (0.87 to 0.96) 0.93 (0.89 to 0.98)
  Azathioprine 1.9 1.5 1.13 (0.99 to 1.31) 1.05 (0.91 to 1.22)
  Cyclophosphamide 1.7 0.7 2.86 (2.05 to 3.99) 2.14 (1.51 to 3.03)
  Gold 7.1 6.5 1.13 (1.04 to 1.23) 1.08 (0.99 to 1.18)
    Anti-tumour necrosis factor therapy 0.1 0.1 1.41 (0.83 to 2.39) 1.48 (0.87 to 2.52)
 Others 1.8 1.7 1.08 (0.93 to 1.25) 1.07 (0.92 to 1.25)
Numbers are percentages unless otherwise stated.
      aRR, adjusted RR, comparing current drug use with no current drug use; CQ/HCQ, chloroquine/hydroxychloroquine  ; DMARD, disease-
modifying antirheumatic drug; model 1, adjusted for all other drugs in the table and glucocorticoids; model 2, model 1 plus further 
adjusted for all other a priori confounders listed in table 2.     
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carefully the risks of glucocorticoid therapy in older patients, 
even at low doses.             
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glucocorticoid therapy more than 45 days before an infection 
would have much less inﬂ  uence upon infection risk than recent 
or current therapy. 
  The low RR of 1.20 is in the range of values that might rea-
sonably be explained by bias.    22    Clinicians may prescribe anti-
infectives at different thresholds to patients under treatment 
with glucocorticoid or DMARD therapy. For example, a patient 
with a sore throat and mild temperature may be more likely 
to receive anti-infectives if immunosuppressed. This would 
increase the relative proportion of cases exposed to glucocor-
ticoid and DMARD therapy, and might explain some of the 
observed effect. We cannot assess whether this explains the 
whole effect, although it seems unlikely. Another concern is 
confounding by disease severity, in which patients with high 
disease activity and thus at higher risk of infection    9    are more 
likely to be prescribed glucocorticoid therapy. Disease severity 
is not measured directly in RAMQ, so we used surrogate mark-
ers that were available, including the number of rheumatologist 
visits in the preceding 6 months and concomitant NSAID use. 
Because these are imperfect surrogates, residual confounding 
will exist. We can, nonetheless, explore whether different lev-
els of disease severity in glucocorticoid-exposed and unexposed 
patients can wholly explain the observed relationship (ie, reduce 
the aRR from 1.2 to 1) using the ‘rule-out approach’.    23    Assuming 
a baseline prevalence of ‘high disease severity’ of 20% in the 
whole cohort and a RR of NSI of 1.27 for this confounder,    9    dis-
ease severity cannot explain the observed aRR of 1.20. Even if 
we assume a doubling of NSI for the 20% of patients with ‘high 
disease severity’, this unmeasured confounder would have to 
be nearly four times more common in glucocorticoid-exposed 
patients to explain fully the observed aRR of 1.2. However, 
while theoretically possible, no binary measure of disease 
severity has yet been reported with such a strong association. 
Finally, there may be confounding by contraindication, in which 
a patient with high comorbidity is considered too ‘high risk’ for 
traditional DMARD therapy and is instead prescribed glucocor-
ticoid therapy. We attempted to adjust for this in the analysis. 
  The results of the dose-dependent analysis suggest that the 
increased risk of NSI exists at a daily dose of 5–10 mg PEQ. It 
may even be present at doses less than 5 mg, although this result 
was inconclusive (aRR 1.10, 0.99 to 1.22). It is interesting to com-
pare the effect sizes between oral glucocorticoid therapy and 
methotrexate. At any dose, glucocorticoid therapy was associ-
ated with a higher RR of NSI compared with that seen with 
methotrexate. This is important to note as some clinicians see 
steroids as the ‘safer choice’ for older patients. The preferential 
prescription of glucocorticoid therapy over methotrexate may 
therefore be misguided with respect to infections, even at low 
doses. Any comparison between the two drugs must, of course, 
take account of all adverse drug reactions and not just NSI. 
Nonetheless, patients treated with glucocorticoid therapy have 
repeatedly been shown to have higher rates of serious infec-
tion than patients treated with methotrexate in observational 
studies.    6        9–12    Older patients are also at high risk of other glu-
cocorticoid-associated adverse events such as osteoporosis and 
cardiovascular disease. The comparative safety of glucocorticoid 
and DMARD therapy, in particular in older patients and patients 
with existing comorbidity, warrants careful consideration. 
  In summary, we have shown that glucocorticoid therapy is 
associated with a modest relative, but high attributable, risk 
of NSI. While some of this association may be explained by 
residual confounding, clinicians should nonetheless consider 
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